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Despite  recent  progress  in  reducing  deaths  attributable  to malaria,  it  continues  to  claim  approximately
500,000  lives  per year  and  is associated  with  approximately  200  million  infections.  New  tools,  includ-
ing  safe  and  effective  vaccines,  are  needed  to ensure  that  the  gains  of the last  15  years are leveraged
toward  achieving  the  ultimate  goal  of malaria  parasite  eradication.  In  2015,  the  European  Medicines
Agency  announced  the  adoption  of  a  positive  opinion  for  the  malaria  vaccine  candidate  most  advanced
in  development,  RTS,S/AS01,  which  provides  modest  protection  against  clinical  malaria;  in early  2016,
WHO  recommended  large-scale  pilot  implementations  of  RTS,S  in  settings  of  moderate-to-high  malaria
transmission.  In alignment  with  these  advancements,  the  community  goals  and  preferred  product  char-
acteristics  for  next-generation  vaccines  have  been  updated  to  inform  the  development  of vaccines  that
are highly  efﬁcacious  in preventing  clinical  malaria,  and  those  needed  to  accelerate  parasite  elimination.
Next-generation  vaccines,  targeting  all  stages  of  the  parasite  lifecycle,  are  in early-stage  development
with  the most  advanced  in  Phase  2 trials.  Importantly,  progress  is being  made  in the deﬁnition  of  feasible
regulatory  pathways  to accelerate  timelines,  including  for vaccines  designed  to  interrupt  transmission  of
parasites  from  humans  to mosquitoes.  The  continued  absence  of  ﬁnancially  lucrative,  high-income  mar-
kets to drive  investment  in malaria  vaccine  development  points  to continued  heavy  reliance  on  public
and  philanthropic  funding.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd. This  is  an  open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/3.0/).. About the disease and pathogen
Malaria is caused by ﬁve species of Plasmodium that infect
umans (Plasmodium falciparum, Plasmodium vivax, Plasmodium
vale spp., Plasmodium malariae and Plasmodium knowlesi) and is
ransmitted by the bite of infected female Anopheline mosquitoes.
he intensity of transmission depends on factors related to the
arasite, the vector, the human host, and the environment. In
013, over 3 billion people were at risk of malaria; there were an
stimated 198 million cases (uncertainty range 124–283 million)
nd 584,000 malaria deaths (uncertainty range 367,000–755,000)
1]. The vast majority of clinical cases (80%) and deaths (90%)
 This is an Open Access article published under the CC BY 3.0 IGO license which
ermits unrestricted use, distribution, and reproduction in any medium, provided
he original work is properly cited. In any use of this article, there should be no
uggestion that WHO  endorses any speciﬁc organisation, products or services. The
se  of the WHO  logo is not permitted. This notice should be preserved along with
he article’s original URL.
∗ Tel.: +1 202 540 4432; fax: +1 202 457 1466.
E-mail address: abirkett@path.org
ttp://dx.doi.org/10.1016/j.vaccine.2015.12.074
264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open acceoccur in sub-Saharan Africa, with children under ﬁve years of
age and primigravid pregnant women most affected [1]. However,
Asia, Latin America, and to a lesser extent the Middle East and
parts of Europe are also affected. In 2013, 97 countries and ter-
ritories had ongoing malaria parasite transmission. According to
the latest WHO  estimates, malaria mortality rates were reduced
by about 47% globally and by 54% in the WHO  African Region
between 2000 and 2013. During the same period, in sub-Saharan
Africa, average infection prevalence in children aged 2–10 years
fell from 26% to 14%—a relative decline of 48% [1]. Despite these
encouraging gains, associated with the scale-up of preventive,
diagnostic and treatment measures, new interventions, including
vaccines to prevent clinical disease and transmission, are urgently
needed [2].
Early diagnosis and treatment of malaria reduces disease and
prevents deaths. It also contributes to reducing malaria parasite
transmission. The best available treatment, particularly for P. falcip-
arum malaria, is artemisinin-based combination therapy (ACT). In
recent years, parasite resistance to artemisinins has been detected
in four countries of the Greater Mekong subregion: Cambodia,
Myanmar, Thailand and Viet Nam. In 2015 it was  reported that
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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esistance to artemisinins has spread across Southeast Asia much
aster than expected and is now in regions of Myanmar close to
ts border with India [3]. If resistance to artemisinins develops
nd spreads to other large geographical areas, most notably sub-
aharan Africa, the public health consequences could be dire, as no
lternative antimalarial medicines will be available for at least ﬁve
ears.
Vector control is the mainstay of reducing malaria parasite
ransmission at the community level from very high levels to
lose to zero. For individuals, personal protection against mosquito
ites represents a ﬁrst line of defence for malaria prevention.
wo forms of vector control are effective in a wide range of cir-
umstances: Insecticide-treated mosquito nets (ITNs) and indoor
praying with residual insecticides (IRS). Currently, vector control
s highly dependent on the use of pyrethroids, which are the only
lass of insecticides currently recommended for ITNs. In recent
ears, mosquito resistance to pyrethroids has emerged in many
ountries. In some areas, resistance to all four classes of insecti-
ides used for public health has been detected. Fortunately, this
esistance has only rarely been associated with decreased efﬁ-
acy, and ITNs and IRS remain highly effective tools in almost
ll settings. However, the use of ITNs does appear to be associ-
ted with selection for changes in mosquito biting behavior, such
s time of day and location of biting, which could reduce their
ffectiveness.
. Overview of current efforts
.1. Biological feasibility for vaccine development
Currently, there are no available malaria vaccines. The Malaria
accine Technology Roadmap (Roadmap) has guided vaccine
evelopment efforts since 2006 [4], and in 2013 was updated based
n extensive consultations with scientists and public health experts
rom non-endemic and malaria-endemic countries, industry, non-
overnmental organizations, and funding agencies [5]. The revised
oadmap focuses on two strategic goals to be met  by 2030: vaccines
o achieve malaria elimination in multiple settings and vaccines
hat are highly efﬁcacious against clinical malaria. The Roadmap
lso includes an updated set of priority areas in research, vaccine
evelopment, key capacities, and policy and commercialization, for
hich further funding and activities are likely to be crucial for suc-
ess [5]. The original Roadmap contained a 2015 landmark goal
or a modestly efﬁcacious malaria vaccine yielding reductions in
orbidity and mortality, which remains unchanged, and could be
chieved by the RTS,S vaccine candidate now under regulatory and
olicy review.
There are three general approaches to developing malaria vac-
ines, targeting different stages of the parasite lifecycle, each
f which is supported by biological evidence that protective
mmune responses are attainable. Pre-erythrocytic vaccines aim
o induce antibodies that block hepatocyte invasion by sporo-
oites and/or cell-mediated immune responses that target infected
epatocytes. Whole parasite and subunit vaccine approaches,
valuated in controlled human malaria infection (CHMI) and/or
eld efﬁcacy studies, have proven to successfully induce PE-stage
mmunity. The scientiﬁc rationale supporting the development
f asexual blood-stage vaccines is rooted in the observation that
aturally acquired immunity can be passively transferred to sus-
eptible individuals. A specialized asexual blood-stage vaccine
pproach targeting pregnancy-associated malaria aims to leverage
bservations that parasite prevalence is highest in ﬁrst preg-
ancy and falls profoundly with each subsequent pregnancy.
inally, development of vaccines to interrupt human-to-mosquito
ransmission is based on studies in avian and primate models2016) 2915–2920
where immunization with extracellular gametes totally sup-
pressed parasite infectivity to mosquitoes on a subsequent blood
meal.
2.2. General approaches to vaccine development for this disease
for low and middle income country markets
Vaccines are needed that target all Plasmodia species that cause
human disease, but most notably P. falciparum and P. vivax [6].
P. falciparum is most prevalent on the African continent, and is
responsible for most deaths from malaria. P. vivax has a wider geo-
graphic distribution, with an estimated 2.5 billion people at risk,
although it is largely absent from the African continent due to the
widespread Duffy-negative phenotype that renders red blood cells
resistant to parasite invasion. The lack of homology between P.
falciparum and P. vivax antigens will likely necessitate the devel-
opment of species-speciﬁc vaccines.
Vaccines to prevent clinical disease target pre-erythrocytic
and/or asexual blood-stage antigens, and are primarily intended
for those enduring the greatest burden of disease; whereas vac-
cines interrupting malaria (parasite) transmission (VIMT) primarily
target pre-erythrocytic and/or sexual, sporogonic and/or mosquito-
stage (SSM) antigens, and are targeted to populations at risk of
endemic transmission. While it may  be possible to develop vac-
cines that are highly effective at both preventing clinical disease
(i.e. cases averted, toward saving lives and preventing disease)
and interrupting the cycle of transmission (i.e. transmission inter-
rupted, to support control and elimination), they are associated
with distinct clinical endpoints, overlapping but different tar-
get populations, discrete Target Product Proﬁles (TPP), regulatory
approval processes, and implementation strategies [6]. In 2015,
WHO  published Preferred Product Characteristics (PPCs) for dis-
ease reducing and transmission reducing malaria vaccines. WHO
PPCs describe preferences for parameters of vaccines from a public
health, rather than a return on investment perspective; in partic-
ular their indications, target groups, and possible immunization
strategies, as well as the clinical data desired related to safety and
efﬁcacy in low and middle income countries [7]. PPCs are meant
to provide early guidance for the development of new products
or the improvement of existing ones. Each PPC addresses early-
stage vaccine research and development (R&D) generally at least
ﬁve to ten years from vaccine availability, and will be reviewed
every ﬁve years, at least, and updated if necessary. PPCs are not
static exit criteria, but are structured in such a way  so as to drive
innovation toward meeting public health needs [7]. In addition to
PPC criteria, vaccine developers targeting WHO  prequaliﬁcation
should consider programmatic suitability criteria deﬁned by WHO
and updated in 2014 [8].
The absence of ﬁnancially lucrative, high-income markets to jus-
tify investment in malaria vaccine development has led to a heavy
reliance on public and philanthropic funding. According to the 2014
G-Finder Report, which reports 2013 global investment for research
and development (R&D) of new products for neglected diseases,
and identiﬁes trends and patterns across the seven years of global
G-FINDER data, funding for malaria R&D in 2013 was  $549 mil-
lion, the lowest level since 2007 [9]. Basic research accounted for
more than a third ($193 million, 35%) of malaria funding, with $119
million (22%) allocated to vaccine development [9].
While different funding agencies have their own  priority focus
areas, they are generally aligned with one of the two Roadmap goals
associated with P. falciparum and with one or more of the four pri-
ority areas. That said, there continues to be a chronic lack of support
for the development of P. vivax vaccines, whether to prevent clini-
cal disease or to prevent transmission, and a lack of support in all
four priority areas of the Roadmap.
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. Technical and regulatory assessment
The absence of robust biomarkers of protection for RTS,S/AS01,
rradiated sporozoites/mosquitoes, infection-treatment vaccina-
ion (ITV), and naturally acquired blood-stage immunity hampers
apid progress in vaccine development. The identiﬁcation of sur-
ogate markers of protection and increased understanding of the
echanism(s) of protection are needed, which may  be achieved via
he increased interrogation from controlled human malaria infec-
ion and ﬁeld efﬁcacy studies.
In the absence of an available vaccine that is recommended
or use, candidates must be evaluated in randomized, “placebo”-
ontrolled, multicenter Phase III efﬁcacy trials. RTS,S/AS01, the
ost advanced malaria vaccine candidate in development globally,
ompleted Phase III evaluation, in January 2014, via a collabora-
ion between GlaxoSmithKline Vaccines (GSK), the PATH Malaria
accine Initiative (MVI), and 13 clinical sites in eight sub-Saharan
frican countries. The co-primary efﬁcacy objectives of the pivotal
fﬁcacy and safety trial (conducted at 11 sites in seven of the eight
ountries) were to evaluate the protective efﬁcacy of RTS,S/AS01E
gainst clinical malaria disease caused by P. falciparum in African
hildren whose age at ﬁrst dose will be from: 1) 6–12 weeks and
ill receive vaccine in co-administration with DTPwHepB/Hib anti-
ens (Tritanrix HepB/Hib) and oral poliovirus vaccine (OPV); and
) 5–17 months. The primary efﬁcacy analysis for both of these
ge categories was for a duration of follow-up of a minimum of 12
onths and a maximum of 18 months after completion of the pri-
ary course. Secondary objectives included evaluation of vaccine
fﬁcacy against severe malaria, anemia, malaria hospitalization,
atal malaria, all-cause mortality, and other serious illnesses includ-
ng sepsis and pneumonia. Efﬁcacy of the vaccine against clinical
alaria under different transmission settings, the evolution of efﬁ-
acy over time, and the potential beneﬁt of a fourth dose were
lso evaluated. Safety of the primary course of immunization and
he fourth dose were studied in both age categories [10]. In June
014, GSK submitted an application for a scientiﬁc opinion by the
ommittee for Medicinal Products for Human Use (CHMP) on RTS,S
hrough the European Medicine Agency’s (EMA) Article 58 proce-
ure. The EMA’s CHMP evaluated data on the quality, safety, and
fﬁcacy of the RTS,S/AS01 vaccine candidate. On Friday July 24,
015, the EMA  announced CHMP’s adoption of a positive opin-
on. This is not licensure, but will be helpful to African regulatory
uthorities as they receive submissions, knowing that a stringent
egulatory authority has provided a positive assessment of quality,
nd risk/beneﬁt. The EMA  assessment does not include aspects such
s feasibility of implementation, cost-effectiveness, and the role of
TS,S in the context of available malaria control measures all of
hich were considered during the WHO  policy recommendation
rocess.
The WHO’s recommendations, published on January 29, 2016,
all for large-scale pilot implementations in settings of moderate-
o-high malaria transmission.
In recent years there has been an increased focus on develop-
ent of a vaccine that interrupts malaria (parasite) transmission
VIMT) to support malaria elimination [5]. The two primary vaccine
evelopment strategies are to induce pre-erythrocytic immunity
hat prevents infection of humans or to induce sexual, sporogonic,
nd/or mosquito-stage (SSM) immunity to prevent transmission
o mosquitoes [6]. While the focus of these vaccines is to prevent
nfection (as opposed to clinical disease), it is important to note that
nfection endpoints have historically not been sufﬁcient to support
accine licensure. Furthermore, SSM–VIMT would not confer direct,
mmediate clinical beneﬁt to the recipient, but could be paired
ith an intervention that provides such a beneﬁt. As such, the
linical beneﬁt that SSM–VIMT provide is primarily a population-
ased long-term beneﬁt associated with reduced incidence of new2016) 2915–2920 2917
malaria parasite infections in humans. This absence of direct and
immediate beneﬁt to the recipient, together with the complexity of
the P. falciparum lifecycle, make clinical development of SSM–VIMT
challenging, particularly for use in the pediatric population.
Deﬁnition of regulatory pathways for next generation malaria
vaccines that interrupt transmission to encourage the develop-
ment of this important class of interventions – while at the same
time safeguarding the health and well-being of the population
that SSM–VIMT are intended to beneﬁt – is urgently needed. One
consideration under active discussion is the potential eligibility of
SSM–VIMT for an Accelerated Approval (AA) method of licensure
by FDA based on a proposed surrogate endpoint with conﬁrmatory
trials performed post-licensure. Resolving this important dilemma
will require vaccine developers and other key stakeholders to work
closely with regulatory authorities, including in endemic counties,
and with the WHO. An important step forward in this regard was
achieved at the inaugural convening of the WHO  Product Devel-
opment for Vaccines Advisory Committee meeting held in Geneva,
September 8–10, 2014, where a speciﬁc recommendation was that
identiﬁcation of a feasible regulatory pathway for SSM–VIMTs be a
priority area of work for the WHO  [11].
The full exploration of the direct feeding assay (DFA), to demon-
strate effective blocking of human-to-mosquito transmission at the
level of the individual as a licensure endpoint will be important, as
will standardization of key functional assays (standard membrane
feedings assay [SMFA], direct membrane feeding assay [DMFA], and
DFA) toward identiﬁcation of correlates of transmission-blocking
immunity.
4. Status of vaccine R&D activities
The current vaccine development pipeline is relatively diverse
in terms of both the stage of parasite lifecycle targeted and the
technology platforms being exploited. The global malaria vaccine
portfolio is maintained at a website managed by WHO  [12]. A
summary of clinical-stage vaccine approaches, by lifecycle stage,
is provided below and Table 1.
4.1. Pre-erythrocytic (PE) vaccines
The most advanced malaria vaccine candidate in development
globally, RTS,S/AS01, completed Phase III clinical testing in 2014.
Results of the co-primary endpoints of the Phase III study after
a year of follow-up were published in November 2011 (for chil-
dren aged 5–17 months) and in December 2012 (for infants aged
6–12 weeks) [13,14]. These results showed that three doses of
RTS,S reduced clinical malaria by approximately half in children
5–17 months of age at ﬁrst vaccination (Intention to Treat analy-
sis). In infants 6–12 weeks of age at ﬁrst vaccination with RTS,S,
clinical malaria was reduced by approximately one-third. In a sub-
sequent analysis after 18 months of follow-up, children aged 5–17
months at ﬁrst vaccination with RTS,S experienced 45% fewer cases
of clinical malaria, compared to children immunized with a control
vaccine. Infants aged 6–12 weeks at ﬁrst vaccination with RTS,S had
27% fewer cases of clinical malaria than infants in the control group
and efﬁcacy waned over time in both age categories [15].
The ﬁnal study results, which analyzed vaccine efﬁcacy,
immunogenicity, safety, and impact of RTS,S/AS01 over a median of
38 and 48 months of follow-up (post-dose 1) in infants and young
children, respectively, including the effect a booster dose of vac-
cine, were published in 2015 [15]. These ﬁnal results demonstrated
that vaccination with the three-dose primary series reduced clinical
malaria cases over the length of the study by 28% in young children
(over a median follow-up of 48 months after ﬁrst dose across trial
sites) and 18% in infants (over a median follow-up of 38 months
2918 A.J. Birkett / Vaccine 34 (2016) 2915–2920
Table 1
Development status of current clinical-stage vaccine candidates (POC = proof of concept trial) (adapted from: WHO  tables of malaria vaccine projects globally—“rainbow
tables” [12].
Candidate name/identiﬁer Developer Phase I Phase IIa POC Phase III
Pre-erythrocytic projects
RTS,S/AS01 delayed fractional third dose GSK Xb
Adenovirus (Ad35) vectored CS and
RTS,S/AS01 in heterologous prime-boost
regimen
GSK Xb
ChAd63/MVA ME-TRAP University of Oxford X
ChAd63/MVA ME-TRAP/Matrix MTM University of Oxford Xb
PfSPZ Sanaria, Inc. Xb
Polyepitope DNA EP1300 NIAID, NIH X
Adenovirus (Ad35) and adenovirus 26
(Ad26) vectored CS in heterologous
prime-boost regimen
GSK Xb
PfCelTOS FMP012/AS01B Ofﬁce of the Surgeon General (US), Department
of the Army (US), USAMRMC
Xb
PfCelTOS FMP012/GLA-SE Ofﬁce of the Surgeon General (US), Department
of the Army (US), USAMRMC
Xb
CSVAC University of Oxford Xb
RTS,S/AS01B + ChAd63/MVA (ME-TRAP) University of Oxford Xb
PfSPZ attenuated sporozoite NIAID, NIH X
rCSP/GLA-SE NIAID, NIH X
ChAd63/MVA (ME-TRAP) co-administered
with RTS,S/AS01B
University of Oxford X
Blood stage projects
EBA175 RII/aluminium phosphate NIAID, NIH X
FMP2.1/AS01B (AMA-1 3D7 E. coli) Ofﬁce of the Surgeon General (US), Department
of the Army (US), USAMRMC, University of
Oxford
Xb
GMZ2/Alhydrogel® European Vaccine Initiative (EVI) X
GMZ2 ﬁeld/Alhydrogel® AMANET, Statens Serum Institut X
PfAMA1-DiCo/GLA-SE or Alhydrogel® Inserm X
P27A/GLA-SE or Alhydrogel® Centre Hospitalier Universitaire Vaudois
(CHUV)
X
MSP3-LSP/AlOH EVI, AMANET X
SE36/AlOH Research Foundation for Microbial Diseases of
Osaka University
X
ChAd63 AMA1/MVA AMA1 University of Oxford X
NMRC-M3V-Ad-PfCA Ofﬁce of the Surgeon General (US), Department
of the Army (US), USAMRMC
Xb
NMRC-M3V-D/Ad-PfCA prime/boost Ofﬁce of the Surgeon General (US), Department
of the Army (US), USAMRMC
Xb
ChAd63/AMA MVA/AMA1
+ Alhydrogel®/CPG7909
University of Oxford Xb
PfPEBS-LSP/AlOH Vac4All X
ChAd63 MSP1/MVA MSP1 University of Oxford Xb
ChAd63 RH5 ± MVA  RH5 University of Oxford X
Sexual stage projects
Pfs25-EPA/Alhydrogel® NIAID, NIH X
Pfs25-VLP/Alhydrogel® Fraunhofer USA X
P.  vivax project
ChAd63/MVA PvDBP University of Oxford X
a Phase II comprises studies of a candidate vaccine that are intended to result in efﬁcacy data in the target population to whom the vaccine would be administered should
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at  eventually by licensed. A program of Phase II studies usually deﬁnes the preferre
hase  II studies also provide an expanded population assessment of the safety of th
b Controlled human malaria infection (CHMI) study.
fter ﬁrst dose across trial sites). A booster dose of RTS,S, adminis-
ered 18 months after completion of the primary series, reduced the
umber of cases of clinical malaria in young children (aged 5–17
onths at ﬁrst vaccination) by 36% over the entire study period
nd in infants (aged 6–12 weeks at ﬁrst vaccination) by 26% over the
tudy period. These results were achieved on top of existing malaria
nterventions, such as ITNs, which were used by approximately 80%
f the trial participants [15].
In both age categories, adverse events after vaccination included
ocal reactions (such as pain or swelling) and fever, which were
bserved more frequently after RTS,S administration compared to
he control vaccine (31% versus 21% of vaccine doses in the 6–12
eek age category and 31% versus 13% in the older 5–17 month
ge category). Very few of the adverse events were severe. In thee, route, and schedule of immunizations that are eventually evaluated for efﬁcacy.
uct.
younger age category (i.e. infants 6–12 weeks of age at ﬁrst injec-
tion), injection site reactions were reported less frequently after
RTS,S administration compared to the standard vaccines routinely
used in the African EPI [14]. RTS,S continued to display a good safety
proﬁle during the entire study period.
In young children, the incidence of fever in the week after
vaccination was higher in those who received the RTS,S vaccine
compared to those who received the control vaccine. In some
children this resulted in febrile reactions which were accompanied
by generalized convulsive seizures, but all those affected fully
recovered within seven days. The rates of serious adverse events
seen in the trial (mainly medical events requiring hospitalization,
regardless of whether they were considered to be caused by
the study vaccine) were comparable between the trial’s RTS,S
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andidate vaccine recipients and those receiving a control vac-
ine, except for cases of meningitis, which were reported in low
umbers, but more often in the RTS,S group compared to the
ontrol.
The meningitis signal previously reported remained in the older
ge category, including a small number of new cases reported after
he fourth dose. This could be a chance ﬁnding as comparisons
ere made across groups for many different diseases, and because
ome of these cases happened years after vaccination without any
bvious relationship to vaccination. If RTS,S is licensed, the occur-
ence of meningitis will be followed closely during Phase IV studies
nd has been ﬂagged as important for the pilot implementations
lso. The pilot implementations are also being designed to deter-
ine whether additional safety concerns, identiﬁed by WHO, are
f signiﬁcance.
Strategies to directly build upon the success of RTS,S, via the
nduction of humoral and cell-mediated immune responses to
he circumsporozoite protein (CSP) and other antigens, have been
nderway for many years. The scientiﬁc rationale for these stud-
es is that a signiﬁcant proportion of RTS,S-immunized volunteers
ot protected following controlled challenge display evidence for
mmunity, as determined by a delay to parasitemia that correlates
ith a >90% reduction in parasites exiting the liver. Currently, there
s a signiﬁcant focus on translational research studies to evaluate
hether vaccine approaches that induce superior anti-CSP anti-
ody responses and/or strong cell-mediated immune responses,
irected at CSP and other antigens, are able to enhance protective
fﬁcacy.
In recent years, one of the most signiﬁcant advances in the
uest to develop highly efﬁcacious pre-erythrocytic vaccines have
een the demonstration that radiation-attenuated P. falciparum
porozoites, administered by ﬁve intravenous doses, protected
/6 volunteers in the highest dose group from infection in CHMI
tudies [16]. Studies are ongoing to replicate these initial ﬁnd-
ngs in larger numbers of volunteers, and to generate evidence
or sustained protection (via delayed challenge) and cross-strain
rotection (via heterologous challenge). Heterologous prime-boost
accine approaches, using different platforms and target antigens,
ave yielded modest levels of protection in CHMI studies [17–19].
.2. Blood-stage (BS) vaccines
While immunity to asexual blood-stage antigens is an impor-
ant mechanism of natural immunity to malaria in endemic regions,
eﬁned biomarkers of protection remain elusive. In recent years,
reliminary evidence for vaccine-induced clinical efﬁcacy from
eld studies has been generated using three blood-stage targets, P.
alciparum AMA1, MSP3 and SERA5. However, as with similar pre-
iminary ﬁndings for other antigens, such as MSP2, further studies
re needed to conﬁrm these initial ﬁndings. Additional antigens
re currently undergoing Phase I and II development, with data
xpected in the coming years. Efforts to develop highly effective
ubunit vaccines targeting asexual blood stages has been buoyed by
rogress in deciphering the redundant network of merozoite inva-
ion mechanisms for P. falciparum,  revealing promising new vaccine
argets. For P. vivax, the challenge of effectively targeting mero-
oite invasion ligands appears to be less complex, with the Duffy
inding protein (DBP) representing the overwhelmingly domi-
ant invasion ligand for ensuring reticulocyte invasion. Protein-
nd vector-based vaccines are expected to enter clinical testing
ver the coming years. Further, whole, attenuated blood-stage
accines for P. falciparum are advancing toward clinical devel-
pment based on promising preclinical data. The most advanced
regnancy-associated malaria vaccine approaches, although still
t the preclinical stage, target var2CSA, which is preferentially2016) 2915–2920 2919
expressed by placental parasites and is the target of acquired immu-
nity over successive pregnancies.
4.3. Sexual, sporogonic, and/or mosquito (SSM) stage vaccines
Clinical studies to evaluate induction of antibodies to sexual,
sporogonic, and/or mosquito-stage antigens, to block human-to-
mosquito transmission, have to date focused on two  antigens (Pfs25
and Pvs25) delivered as either recombinant proteins or via attenu-
ated vaccinia virus; however, high levels of transmission-blocking
activity have not been reported. Additional target antigens, includ-
ing Pfs48/45,  Pfs230, HAP2, and AnAPN1, have been associated with
promising preclinical data.
5. Likelihood for ﬁnancing
To ensure ﬁnancing is available for vaccines that will support
malaria eradication and elimination, it will be important to build
strong support early on in its development. The Roadmap goal
will be a good starting point for such a dialogue with potential
ﬁnancing organizations. Traditionally vaccine ﬁnancing has gone
to support children under age ﬁve to prevent disease and death,
however, recently Gavi, the Vaccine Alliance, has supported the
Global Polio Eradication Initiative, the MenAfriVac vaccine and HPV
(both vaccines are provided outside of the EPI infant schedule), as
well as Ebola (a commitment was made in December 2014 to pur-
chase Ebola vaccines for at-risk populations). These relatively new
commitments demonstrate that there is support for considering
vaccination in a different context.
The Global Fund for AIDS, Tuberculosis and Malaria (GFATM) has
been ﬁnancing countries that are in the malaria pre-elimination
phase with WHO-recommended tools. Although GFATM has yet to
be involved in vaccine ﬁnancing (there are no vaccines for AIDS or
malaria, nor any new vaccines for TB), as vaccines become available
for these diseases, GFATM will have to deﬁne its role in integrat-
ing vaccine use into broader efforts of preventing, treating, and/or
interrupting transmission of these three major diseases. Dialogue
between GFATM and Gavi on malaria vaccines has already started,
as their ﬁnancing mechanisms and models and areas of exper-
tise are different. Their interactions on RTS,S will help to pave the
way for future dialogue between these two key potential global-
level ﬁnanciers and help determine the optimal roles of the two
organizations.
As part of the planning process to help secure ﬁnancing, MVI
will develop and update business and investment cases as a vac-
cine moves through the development pathway. As indicated in the
Roadmap, “business cases would need to be developed prior to
investment in each stage of development. Prior to proof of concept,
a business case would include a value proposition (i.e. a statement
that clearly identiﬁes what advantages a customer will receive
by purchasing the vaccine), PPCs, estimated development costs,
options for ﬁnancing, and an initial market assessment. Prior to
entering into Phase III, the case would be more comprehensive
and would be developed and agreed upon among manufacturers,
donors, WHO, global-level ﬁnanciers, and countries. This process
will be especially important for an eradication agenda. The detailed
business case prior to Phase III would include a value proposition,
a TPP, late stage development costs, a ﬁnancing plan, a strategic
demand forecast, estimated capital costs, and pricing assumptions.”
The business and investment cases will be key documents to enable
global-level ﬁnancing bodies to understand their potential role in
ﬁnancing malaria vaccines for elimination and eradication.Conﬂict of interest statement
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